1238 results about "Adjuvant" patented technology

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention discloses application of 4, 5-dialkyl imidazole cationic lipid in a drug brain delivery carrier, and belongs to the field of drug delivery. The 4-site and the 5-site of imidazole are respectively modified with alkyl with not less than 10 carbon atoms to form the 4, 5-dialkyl imidazole cationic lipid. The 1, 4, 5-dialkyl imidazole cationic lipid is mixed with a therapeutic drug and other lipid auxiliary materials to prepare drug-loaded lipid nanoparticles loaded with the therapeutic drug, and the drug-loaded lipid nanoparticles can be used as a drug delivery system for brain delivery of the therapeutic drug. The 1, 4, 5-dialkyl imidazole cationic lipid has the function of dynamically regulating and controlling opening and closing of a blood brain barrier, and reversible opening of the blood brain barrier can be achieved; the formed drug carrier can pass through a blood brain barrier and well realize brain delivery of loaded therapeutic drugs, and a new strategy is provided for brain delivery of different types of drugs.

The invention belongs to the technical field of biological medicine, and discloses a novel adjuvant recombinant herpes zoster vaccine and a preparation method thereof. The vaccine is composed of gE-gD protein and a liposome adjuvant, the liposome adjuvant is prepared by the following steps: co-dissolving 3D-MLA, phospholipid-containing components and steroid components in an organic solvent to form a film, hydrating and homogenizing with PBS, finally adding QS-21, and fixing the volume with PBS. According to the process, enhanced components are uniformly and stably anchored in a membrane phase micro-domain, and the particle structure is controllable. Under the same antigen dosage and detection caliber, the D28 GMC of the vaccine is obviously improved, and more sufficient and stronger primary humoral immune response is embodied.

The invention relates to the technical field of pharmaceutical preparations, in particular to a multiple nano emulsion adjuvant and a preparation method thereof. The multiple nano emulsion adjuvant is prepared from 2.73 to 6.37 g of an oil phase matrix based on 100 g of a raw material system, 0.10 to 0.25 g of a sterol compound; 0.212 to 0.424 g of a nonionic surfactant; 0.00050 to 0.00200 g of a triterpenoid saponin type active adjuvant; 0.010 to 0.020 g of an anionic polymer modifier; 0.005 to 0.015 g of a cationic polymer modifier; 70-90 g of a buffer solution; the total mass of the raw materials is 100 g. The nano emulsion adjuvant prepared by the invention can be stored for 6 months at 2-8 DEG C under a low sterol condition, the particle size change does not exceed + 5%, no crystallization or layering is generated, and the stability of the active adjuvant is remarkably improved.

The invention discloses a novel herpes zoster vaccine composition and a preparation method, and belongs to the technical field of vaccines. The novel herpes zoster vaccine composition comprises gE protein and an adjuvant, the adjuvant is selected from at least one of an aluminum salt adjuvant, a saponin adjuvant, a TLR pathway agonist, an STING pathway agonist, an emulsion adjuvant and a liposome adjuvant. The invention also provides a preparation method of the composition. Compared with the prior art, the gE protein prepared by the method disclosed by the invention has the advantages that a protective matrix is jointly constructed by saccharides capable of forming a glassy state and a buffer system, and conformation is fixed through hydrogen bond replacement and vitrification in freezing and drying processes, so that interface-induced folding and aggregation are reduced; a small amount of surfactant weakens air-liquid and solid-liquid interfacial tension, terminal low-adsorption filtration reduces non-specific adsorption loss, and the monomer state and immunogenicity are maintained after redissolution.

The invention relates to the technical field of medicine analysis and detection, and particularly discloses a method for detecting the content of protein in a 3D-MLA adjuvant, which comprises the following steps: (1) preparing a test solution: firstly dissolving the 3D-MLA adjuvant by using a hydrochloric acid solution, performing 300-600W ultrasonic treatment for 2-5min, centrifuging 10000-13000g for 4-7min, and taking supernate; adding a compound enzyme into the supernate for enzymolysis; then adding concentrated hydrochloric acid, uniformly mixing, hydrolyzing for 20 + / -2 hours in a nitrogen atmosphere at 105-115 DEG C, blow-drying, and dissolving with a hydrochloric acid solution to obtain a test sample stock solution; adding a derivatization reagent into the test sample stock solution, and carrying out derivatization treatment, extraction and dilution to obtain a test sample solution; and (2) high performance liquid chromatography determination. According to the detection method provided by the invention, the residual quantity of the host cell protein in the 3D-MLA can be rapidly and accurately determined, and the quality control of the 3D-MLA is realized.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.

The present invention discloses a method for detecting MPL in a sample and its related applications, relating to the field of biological detection. The adsorbent includes aluminum phosphate or a product obtained by mixing aluminum hydroxide and a phosphate solution, which can effectively adsorb free MPL in the sample, thereby achieving effective separation of free MPL and MPL bound to liposomes in the sample. By detecting the difference in MPL content in the sample before and after adsorption, the proportion of free MPL and MPL bound to liposomes in the sample can be determined. This method has the advantages of being easy to implement, low cost, and high efficiency. It does not require expensive reagents and instruments, and can quickly and accurately calculate the encapsulation rate of MPL in liposomes, providing a new approach for quality control of adjuvants or vaccines containing MPL.

The application belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody specifically recognizing type II grass carp reovirus VP4 protein, a eukaryotic expression method and application. The S6 gene in GCRV-II encodes VP4 protein, the application transfects the target gene S6 into HEK293 cells for expression and purification, cooperates with Freund's adjuvant to immunize New Zealand white rabbits, and uses ELISA, single B cell screening and eukaryotic expression technology to obtain a rabbit-derived recombinant monoclonal antibody specifically recognizing GCRV-II VP4 protein. The antibody has strong specificity, provides support for further establishment of specific type II grass carp reovirus diagnosis technology, and has great application value for development of GCRV-II related scientific research.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and / or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.

The invention relates to the technical field of biological medicines, in particular to a vaccine for treating or preventing hepatitis B virus infection. The vaccine comprises a hepatitis B surface antigen and a composite adjuvant, wherein the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21, and the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21; the nucleotide sequence of the CpG oligodeoxynucleotide is as shown in SEQ ID NO. 1. According to the vaccine provided by the invention, an HBsAg antibody can be generated in a normal mouse body, and HBV in an HBV-carrier mouse can be effectively eliminated, so that the vaccine has the effect of treating or preventing hepatitis B virus infection. According to the vaccine provided by the invention, two adjuvants, namely CpG oligodeoxynucleotide and saponin QS-21, are adopted, so that the vaccine can be used for synergistically activating an immune effect, enhancing the activation of B cells and permanently transforming into plasma cells, and meanwhile, the vaccine can be used for resisting immune tolerance of T cells, realizing the removal of hepatitis B viruses and realizing functional cure of clinical hepatitis B treatment.

The invention discloses a preparation method of an aluminum hydroxide adjuvant capable of regulating and controlling pH in stages, and aims to solve the problems of non-uniform particle size, unstable adsorption and large inter-batch difference in the traditional process. According to the method, phosphate radical modified hydroxyapatite nanocrystal seeds are taken as an induction template, and three-stage accurate pH regulation and control are carried out: a pre-crystal seed stage activates crystal seed active sites, a main crystallization stage guides directional growth of aluminum hydroxide, and an aluminum phosphate coating layer is formed in a stabilization stage. Compared with a traditional process, the finished product yield is improved, energy consumption is reduced, and the method is suitable for vaccine industrial production.

The invention discloses a QS-21 composite adjuvant and a preparation method thereof, and belongs to the technical field of biological medicines. According to the QS-21 composite adjuvant, a polyanion material and QS-21 are compounded to form nanoparticles, and the nanoparticles are organically combined with a freeze-drying protective additive, so that the prepared QS-21 composite adjuvant is relatively high in retention rate, the problems of hydrolysis and oxidation are solved, the requirement of a phospholipid carrier is avoided, and a vaccine co-preparation process is simplified; the subsequently added freeze-drying protective agent retains the immune enhancement activity of the QS-21 and reduces the exposure of the QS-21 to a degradation environment; the corresponding cytotoxicity meets the standard, and the hemolysis rate is low; therefore, the method has remarkable clinical application value and industrialization potential.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and an antigen and / or immunostimulatory agent(s) bound to its surface are provided. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The antigen and / or immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be eOD-GT8. The immunostimulatory agent can be, e.g., T cell epitope such as a pan HLA DR-binding epitope (PADRE) and / or a lectin such as MBL or C3, or ligand thereof such as a glycan including mannose. Also provided are antigen-T cell epitope fusions such as eOD-PADRE and nanostructures presenting the same. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses are also provided.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

The invention discloses an RSV pre-F tripolymer protein combination and application thereof in preparation of bivalent RSV vaccines, and relates to the technical field of human vaccines. The vaccine is prepared by mixing an RSV-A subtype pre-F tripolymer protein and an RSV-B subtype pre-F tripolymer protein in equal mass, and matching with an aluminum hydroxide adjuvant with the concentration of 0.35 mg / 0.5 mL. A p27 fragment and a C-terminal esterification region of each of the two F proteins are deleted, the two F proteins are connected with F2 / F1 through GSGSGS, inter-chain disulfide bonds are introduced to S146C / N460C and A149C / Y458C sites respectively, intra-chain disulfide bonds are introduced to S155C / S290C sites respectively, and stable pre-F trimers are spontaneously assembled after secretion expression of CHO cells; the vaccine does not need to be freeze-dried, still keeps high purity and neutralizing epitope integrity after being stored at 37 DEG C for 28 days, can obviously induce neutralizing antibody and T cell immunity, and can be used for preventing various RSV-A / B infections.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a blood-activating and detoxifying traditional Chinese medicine formula and a nanogel preparation method thereof. The invention provides a traditional Chinese medicine formula for promoting blood circulation and removing toxicity and a nanogel preparation method of the traditional Chinese medicine formula for promoting blood circulation and removing toxicity to solve the problem that in the prior art, a good external application traditional Chinese medicine formula capable of being used for skin with damp-heat toxin accumulation does not exist, and the traditional Chinese medicine formula for promoting blood circulation and removing toxicity and the nanogel preparation method of the traditional Chinese medicine formula for promoting blood circulation and removing toxicity comprise monarch drugs, ministerial drugs, adjuvant drugs and conductant drugs, the ministerial drugs comprise honeysuckle flowers, fructus forsythiae, paris polyphylla, cortex dictamni and fructus kochiae, the adjuvant drugs comprise radix salviae miltiorrhizae, flos carthami, garden balsam stems and centella asiatica, and the conductant drug comprises bletilla striata. The traditional Chinese medicine composition provided by the invention is precise and appropriate in compatibility and distinct in gradation, and can form a synergistic treatment chain of clearing heat, detoxifying, activating blood and promoting tissue regeneration, so that the wound healing speed of the skin surface is accelerated, and the traditional Chinese medicine composition has a relatively good curative effect on damp-heat and toxic stasis type skin diseases.

The invention discloses a fresh plant directed biotransformation method based on endogenous enzyme activation and a product and application thereof. The core of the preparation method is as follows: fresh plants (tuberous roots, stems or fruits) which are harvested in a ripe state and have metabolism in a dormant state (the respiration rate is lower than 5 mg CO / kg.h) are taken as raw materials, the raw materials are treated in an environment with the specific pressure being 0.02-0.20 MPa, the temperature being 70-121 DEG C and the humidity being 50-95%, a specific impregnating compound can be selectively combined, and the raw materials can be prepared into the plant culture medium. Under the conditions that exogenous microorganisms are not introduced and plant tissue structures are not damaged, the catalytic function of an endogenous metabolic enzyme system is safely and efficiently restarted and maximally promoted, and components of a plant body are driven to realize directional biotransformation. According to the process, conversion of primary metabolites and / or secondary metabolites is remarkably promoted, the content conversion of one or more beneficial components in the primary metabolites and / or the secondary metabolites is improved, and meanwhile, the biological and pharmaceutical structures and inherent metabonomics characteristics of the plants are completely reserved. The biotransformation product can be used as a high-quality raw material to be applied to medicines, common foods, health foods, special diet foods, daily chemical products and disinfection products, and can be further prepared into traditional Chinese medicine decoction pieces, solid preparations, semi-solid preparations and liquid preparations by adding or not adding pharmaceutically acceptable auxiliary materials.

The invention belongs to the technical field of animal immunopotentiators, and particularly relates to an oil-in-water type veterinary adjuvant and a preparation method thereof. The oil-in-water type veterinary adjuvant comprises white oil, span 80, Tween 80, PEG400, astragalus polysaccharide and a phosphate buffer solution, the astragalus polysaccharide cooperates with a surfactant to activate a TLR4 / NF-kappa B pathway, Th1 / Th2 / Th17 three-way immune response is achieved, the serum IgG and mucous membrane sIgA antibody level is remarkably improved, and the problems that a traditional O / W adjuvant is high in layering rate (smaller than 5%), and the stability of the traditional O / W adjuvant is poor are solved through compound optimization of the HLB value (HLB = 11.5-12.0) of the HLB value of span 80 and Tween 80. And storage at 4 DEG C for 90 days) and poor freeze-thaw stability are solved.

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.

The invention relates to a preparation method of a biological membrane with a bionic cuticle'brick-slurry 'structure and a wound dressing application of the biological membrane, and belongs to the technical field of biological auxiliary materials. The preparation method comprises the following steps: dispersing prepared wool keratin microspheres in a fibroin solution, realizing a stable and firm brick-slurry structure by combining solvent volatilization with a photo-crosslinking technology, further crosslinking by utilizing metal ion coordination, and simultaneously endowing the dressing with the capabilities of effectively blocking bacterial permeation and sterilizing. The biological membrane exceeds the design of traditional layered wound dressings, and accurate reproduction of a natural skin structure is preferentially considered. The microspheres are assembled into a densely-arranged masonry structure material in a planned manner, so that the dressing has high moisture permeability, oxygen permeability and strong antibacterial barrier capacity, can promote repair of infectious wounds and burn and scald wounds, and has remarkable clinical application value.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

The invention discloses a mannose modified liposome gel microsphere oral delivery system based on cations and application of the mannose modified liposome gel microsphere oral delivery system. The oral delivery system comprises a core layer and a wrapping layer, the core layer is mannose modified cationic liposome loaded with a mucous membrane adjuvant retinoic acid and an antigen, and the wrapping layer is sodium alginate gel vulcanized and modified by cysteine. The mannose modified cationic liposome is prepared by coupling mannose on the surface of the cationic liposome, and the cysteine modified sodium alginate gel is used for protecting antigens in the core layer from being eroded by gastric juice, enhancing the adhesiveness of a delivery system in the intestinal tract and prolonging the retention time of the delivery system in the intestinal tract; in addition, the R-MLip can be expanded and released under the environment that the pH of the intestinal tract is increased. The inside of the gel microsphere of the oral delivery system shows a regular net-shaped structure and has abundant holes and channels, and the oral delivery system shows a good prospect in the aspect of enhancing mucous membrane and systemic immunity and possibly becomes a potential substitute of a traditional attenuated live vaccine in the future.